Press Release
May 17, 2024

ARTBIO and Fog Pharmaceuticals Collaborate on Research

The Life Sciences team advised ARTBIO, Inc. in a research collaboration with Fog Pharmaceuticals, Inc.

The ARTBIO-FogPharma collaboration will leverage both companies’ proprietary discovery & development platforms to create a new class of alpha radioligand therapeutics that will maximize efficacy and transform patient outcomes. ARTBIO will leverage its AlphaDirect™ platform to enable development and distributed manufacturing of alpha radioligand therapies (ARTs) while FogPharma will leverage its proprietary Helicon™ platform of ultratunable peptides to drive invention of the ideal peptide to carry such ARTs to tumors.

ARTBIO is a clinical-stage radiopharmaceutical company focused on developing a new class of alpha radioligand therapies (ARTs) by selecting the optimal alpha-precursor isotope (212Pb) and tumor-specific targets to create therapeutics with the potential for highest efficacy and safety.

The Goodwin team was led by Christopher Denn and Frank Qin.

For more details, read the press release and articles in Business Wire and BioPharma Drive.